A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

D3 Bio Investigative Site, Detroit, Michigan, United States

D3 Bio Investigative Site, New York, New York, United States

D3 Bio Investigative Site, Nashville, Tennessee, United States

D3 Bio Investigative Site, Blacktown, New South Wales, Australia

D3 Bio Investigative Site, Macquarie Park, New South Wales, Australia

D3 Bio Investigative Site, Bedford Park, South Australia, Australia

D3 Bio Investigative Site, Nedlands, Western Australia, Australia

D3 Bio Investigative Site, Beijing, Beijing Municipality, China

D3 Bio Investigative Site, Guangzhou, Guangdong, China

D3 Bio Investigative Site, Harbin, Heilong Jiang, China

D3 Bio Investigative Site, Wuhan, Hubei, China

D3 Bio Investigative Site, Shanghai, Shanghai Municipality, China

D3 Bio Investigative Site, Hangzhou, Zhejiang, China

D3 Bio Investigative Site, Seoul, South Korea